Enrique Grande: Cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma

Enrique Grande, Head of Oncology at MD Anderson Madrid Cancer Center, recently shared a post on X:

“Investigating cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma after prior immunotherapy.

Results show similar time to next therapy and overall survival for both regimens, aligning with phase 3 CONTACT-03 trial results.”

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor

Authors: Georges Gebrael MD, Yeonjung Jo MS, Vinay Mathew Thomas MD, Haoran Li MD, PhD, Nicolas Sayegh MD, Nishita Tripathi MD, Ayana Srivastava, Blake Nordblad MSCR, Emre Dal MD, Arshit Narang MBBS, James Brundage MS, Patrick Campbell MD, Gliceida Galarza Fortuna MD, Chadi Hage Chehade MD, Benjamin L. Maughan MD, PharmD, Neeraj Agarwal MD, FASCO, Umang Swami MD, MS

Source: Enrique Grande/X